The Federal Trade Commission is exploring how drug distributors and group-purchasing organizations may be contributing to ongoing shortages of generic drugs at health care facilities.
Why it matters: It's the latest effort to untangle a complex web of factors driving high levels of shortages in the United States, which have affected cancer drugs and antibiotics, among others.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,